Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 2/2015

01.06.2015 | Original Article

Time Dependent Release of Interleukin-8 and Tumor Necrosis Factor-α in Platelet Concentrate

verfasst von: Rinku V. Shukla, Tanvi G. Patel, Snehalata C. Gupte

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Contaminating white blood cells in stored platelet concentrate (PC) are the source of many pro-inflammatory cytokines. These are implicated in transfusion reactions. To study the release of interleukin (IL)-8 and tumor necrosis factor alpha (TNF-α) at different time interval in PC prepared by-platelet rich plasma (PRP) and buffy coat (BC) using different principles. Fifteen PCs were prepared by both the methods. The supernatants of PCs prepared by PRP and BC methods were collected aseptically after 1, 18, 65 and 112 h of preparation. pH, platelet and WBC counts were done. The supernatants were frozen in aliquots at −56 °C for measurement of IL-8 and TNF-α concentration using ELISA. The Mean ± SD value of WBC in PRP-PC was 7.4 ± 3.75 × 107 and in BC-PC 3.9 ± 2.2 × 107. The mean platelet counts were 6.05 ± 1.94 × 1010 and 6.54 ± 2.18 × 1010 respectively. The highest level of IL-8 in one hour was up to 30 pg/ml in both the type of PC. It increased up to 986 pg/ml in PRP-PC and 481 pg/ml in BC-PC at 112 h. IL-8 increased significantly during storage period of 5 days in both types of PCs (P0.000 and P0.01). TNF-α level remained low up to 18 h. The highest level was 72 pg/ml in PRP-PC and 57 pg/ml in BC-PC at 65 h. IL-8 levels significantly increased after one hour of storage and TNF-α. levels were low up to 18 h and then showed increase. The BC-PC had significantly low levels of IL-8 compared to PRP-PC (P0.0001).
Literatur
1.
Zurück zum Zitat Fujihara M, Takahashi TA, Ogiso C, Hosoda M, Ikebuchi K, Sekiguchi S (1997) Generation of interleukin 8 in stored apheresis platelet concentrates and the preventive effect of prestorage ultraviolet B radiation. Transfusion 37:468–475CrossRefPubMed Fujihara M, Takahashi TA, Ogiso C, Hosoda M, Ikebuchi K, Sekiguchi S (1997) Generation of interleukin 8 in stored apheresis platelet concentrates and the preventive effect of prestorage ultraviolet B radiation. Transfusion 37:468–475CrossRefPubMed
2.
Zurück zum Zitat Aye MT, Palmer DS, Giulvi A, Hashemi S (1995) Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion 35:117–124CrossRefPubMed Aye MT, Palmer DS, Giulvi A, Hashemi S (1995) Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion 35:117–124CrossRefPubMed
3.
Zurück zum Zitat Shaiegan M, Pourfatollah A, Namiri M, Babace G (2006) Generation of IL-8 and TNF alpha in platelet concentrates during storage. Arch Iran Med 9:61–64PubMed Shaiegan M, Pourfatollah A, Namiri M, Babace G (2006) Generation of IL-8 and TNF alpha in platelet concentrates during storage. Arch Iran Med 9:61–64PubMed
4.
Zurück zum Zitat Bayraktarogglu Z, Yilmaz N, Cicek HK, Karafak A, Gul E (2007) Platelet storage time and cytokine (IL-2R, IL-8, TNF- α) levels. East Mediterr Health J 13(1):79–83 Bayraktarogglu Z, Yilmaz N, Cicek HK, Karafak A, Gul E (2007) Platelet storage time and cytokine (IL-2R, IL-8, TNF- α) levels. East Mediterr Health J 13(1):79–83
5.
Zurück zum Zitat Benson K, Branch DR, Calhoun L, Dzik WH, Leparc GF, McMican A et al (1996) Blood and components. In: Tyler VV (ed) AABB technical manual, 12th edn. American Association of Blood Banks, Bethesda, pp 139–141 Benson K, Branch DR, Calhoun L, Dzik WH, Leparc GF, McMican A et al (1996) Blood and components. In: Tyler VV (ed) AABB technical manual, 12th edn. American Association of Blood Banks, Bethesda, pp 139–141
6.
Zurück zum Zitat Bharucha ZS, Chiewsilp P, Bhasin R (2002) Model standard operating procedures for Blood Transfusion Service. WHO, New Delhi Bharucha ZS, Chiewsilp P, Bhasin R (2002) Model standard operating procedures for Blood Transfusion Service. WHO, New Delhi
7.
Zurück zum Zitat Holme S, Murphy S (1978) Quantitative measurements of platelet shape by light transmission studies: application to storage of platelets for transfusion. J Lab Clin Med 92:53–64PubMed Holme S, Murphy S (1978) Quantitative measurements of platelet shape by light transmission studies: application to storage of platelets for transfusion. J Lab Clin Med 92:53–64PubMed
8.
Zurück zum Zitat Chaudhary R, Aggarwal A, Khetan D, Dayal R (2006) Cytokine generation in stored platelet concentrate: comparison of two methods of preparation. Indian J Med Res 124:427–430PubMed Chaudhary R, Aggarwal A, Khetan D, Dayal R (2006) Cytokine generation in stored platelet concentrate: comparison of two methods of preparation. Indian J Med Res 124:427–430PubMed
9.
Zurück zum Zitat Welsh KJ, Burgoss H, Batchelor R (1977) Immune response to allogenic rat platelets: ag B antigens in matrix lacking Ia. Eur J Immunol 7:267–272CrossRefPubMed Welsh KJ, Burgoss H, Batchelor R (1977) Immune response to allogenic rat platelets: ag B antigens in matrix lacking Ia. Eur J Immunol 7:267–272CrossRefPubMed
10.
Zurück zum Zitat Claas FHG, Smeenk RJT, Schmidt R (1981) Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leucocytes in the platelet suspension. Exp Hematol 9:84–89PubMed Claas FHG, Smeenk RJT, Schmidt R (1981) Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leucocytes in the platelet suspension. Exp Hematol 9:84–89PubMed
11.
Zurück zum Zitat Van Kooy MM, Van Prooijen HC, Moes M, Stants IB, Akkerman J-WN (1991) Use of leukocyte depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 77:201–205 Van Kooy MM, Van Prooijen HC, Moes M, Stants IB, Akkerman J-WN (1991) Use of leukocyte depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 77:201–205
12.
Zurück zum Zitat Gouttefangeas C, Diehl M, Keilholz W, Hornlein RF, Stevanovic S, Rammensee HG (2000) Thrombocyte HLA molecules retain non renewable endogenous peptides of megakaryocytic lineage and do not stimulate direct allocytotoxicity in vitro. Blood 95(10):3168–3175PubMed Gouttefangeas C, Diehl M, Keilholz W, Hornlein RF, Stevanovic S, Rammensee HG (2000) Thrombocyte HLA molecules retain non renewable endogenous peptides of megakaryocytic lineage and do not stimulate direct allocytotoxicity in vitro. Blood 95(10):3168–3175PubMed
13.
Zurück zum Zitat Sirchia G, Parravicini A, Rebulla P (1982) Effectiveness of red blood cells filtered through cotton wool to prevent anti leukocyte antibody production in multitransfused patients. Vox Sang 42:190–197CrossRefPubMed Sirchia G, Parravicini A, Rebulla P (1982) Effectiveness of red blood cells filtered through cotton wool to prevent anti leukocyte antibody production in multitransfused patients. Vox Sang 42:190–197CrossRefPubMed
14.
Zurück zum Zitat Saarinen UM, Kekomaki R, Siimes MA (1990) Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte free blood components. Blood 75:512–517PubMed Saarinen UM, Kekomaki R, Siimes MA (1990) Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte free blood components. Blood 75:512–517PubMed
15.
Zurück zum Zitat Novotny VNJ, Doorn R, Witvliet MD (1995) Occurrence of allogenic HLA and non-HLA antibodies after transfusion of pre storage filtered platelets and red blood cells: a prospective study. Blood 85:1736–1741PubMed Novotny VNJ, Doorn R, Witvliet MD (1995) Occurrence of allogenic HLA and non-HLA antibodies after transfusion of pre storage filtered platelets and red blood cells: a prospective study. Blood 85:1736–1741PubMed
16.
Zurück zum Zitat Heddle NM, Blajman A, Meyer RM, Lipton JH, Walker IR, Sher GD et al (2002) A randomized controlled trial comparing the frequency of acute reactions to plasma removed platelets and pre storage WBC reduced platelets. Transfusion 42:556–566CrossRefPubMed Heddle NM, Blajman A, Meyer RM, Lipton JH, Walker IR, Sher GD et al (2002) A randomized controlled trial comparing the frequency of acute reactions to plasma removed platelets and pre storage WBC reduced platelets. Transfusion 42:556–566CrossRefPubMed
17.
Zurück zum Zitat Davenport RD, Burdick M, Strieter RM, Kunkel SL (1994) Monocyte chemoattractant protein production in red cell incompatibility. Transfusion 34:16–19CrossRefPubMed Davenport RD, Burdick M, Strieter RM, Kunkel SL (1994) Monocyte chemoattractant protein production in red cell incompatibility. Transfusion 34:16–19CrossRefPubMed
18.
Zurück zum Zitat Wadhwa M, Krailadsiri P, Dilger P, Gaines Des R, Seghatchian MJ, Thorpe R (2002) Cytokine levels as performance indicators for white blood cell reduction of platelet concentrates. Vox Sang 35:199–203 Wadhwa M, Krailadsiri P, Dilger P, Gaines Des R, Seghatchian MJ, Thorpe R (2002) Cytokine levels as performance indicators for white blood cell reduction of platelet concentrates. Vox Sang 35:199–203
19.
Zurück zum Zitat Cardigan R, Sutherland J, Wadhwa M, Dilger P, Thorpe R (2003) The influence of platelet additive solutions on cytokine levels and complement activation in platelet concentrates during storage. Vox Sang 24:28–35CrossRef Cardigan R, Sutherland J, Wadhwa M, Dilger P, Thorpe R (2003) The influence of platelet additive solutions on cytokine levels and complement activation in platelet concentrates during storage. Vox Sang 24:28–35CrossRef
20.
Zurück zum Zitat Flegel WA, Wiesneth M, Stampe D, Koerner K (1995) Low cytokine contamination in buffy coat derived platelet concentrate without filtration. Transfusion 35:917–920CrossRefPubMed Flegel WA, Wiesneth M, Stampe D, Koerner K (1995) Low cytokine contamination in buffy coat derived platelet concentrate without filtration. Transfusion 35:917–920CrossRefPubMed
21.
Zurück zum Zitat Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME (1993) Increased tumor necrosis factor, interleukin 1, and interleukin 6 levels in the plasma of stored platelet concentrates: relationship between TNF α and IL-6 levels and febrile transfusion reactions. Transfusion 33:195–199CrossRefPubMed Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME (1993) Increased tumor necrosis factor, interleukin 1, and interleukin 6 levels in the plasma of stored platelet concentrates: relationship between TNF α and IL-6 levels and febrile transfusion reactions. Transfusion 33:195–199CrossRefPubMed
Metadaten
Titel
Time Dependent Release of Interleukin-8 and Tumor Necrosis Factor-α in Platelet Concentrate
verfasst von
Rinku V. Shukla
Tanvi G. Patel
Snehalata C. Gupte
Publikationsdatum
01.06.2015
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 2/2015
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-014-0435-8

Weitere Artikel der Ausgabe 2/2015

Indian Journal of Hematology and Blood Transfusion 2/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.